CADL Candel Therapeutics, Inc.
Candel Therapeutics, Inc. (CADL) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $2.5M.
Where they traded
Last open-market purchase: February 23, 2026 , by Manning Paul B .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Tak Paul Peter | Chief Executive Officer | Sell 10b5-1 | 59,379 | $10.46 | $620.9K | 113,321 −34.4% of holding | |
| Tak Paul Peter | Chief Executive Officer | Sell 10b5-1 | 220,866 | $11.50 | $2.5M | 172,700 −56.1% of holding | |
| Tyagarajan Seshu | Chief Technology Officer | Sell 10b5-1 | 7,000 | $12.00 | $84.0K | 76,865 −8.3% of holding | |
| Barone Francesca | Chief Scientific Officer | Sell 10b5-1 | 23,447 | $10.06 | $235.8K | 77,362 −23.3% of holding | |
| Tyagarajan Seshu | Chief Technology Officer | Sell 10b5-1 | 7,000 | $10.02 | $70.2K | 83,865 −7.7% of holding | |
| Manning Paul B | Director | Buy | 550,458 | $5.45 | $3.0M | 2,763,527 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.